Cantor Fitzgerald Downgrades Ardelyx to Neutral
Cantor Fitzgerald analyst Louise Chen downgrades Ardelyx (NASDAQ:ARDX) from Overweight to Neutral.
Ardelyx Q1 EPS $(0.21) Beats $(0.22) Estimate
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 38.24 percent increase over losses of $(0.34) per share from the same
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 points on Monday.
Mid-Day Market Update: Crude Oil Tumbles Over 6%; Nkarta Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 400 points on Monday.
Why Ardelyx Shares Are Rising
Ardelyx Inc (NASDAQ: ARDX) shares are trading higher by 29.32% at $0.97 after the company reported it received an interim response from the OND, CDER and FDA for the company’s second level of appeal of the Complete Response Letter for XPHOZAH.
FDA Plans To Convene AdComm For Ardelyx’s Tenapanor For CKD Patients On Dialysis
The FDA’s Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), has provided an interim response to Ardelyx…
26 Stocks Moving in Monday’s Pre-Market Session
Gainers
ERYTECH Pharma S.A. (NASDAQ: ERYP) shares rose 88.4% to $2.30 in pre-market trading. Erytech Pharma recently announced publication of results from Eryapasse Phase 2 trial as treatment for hypersensitive ALL in the British Journal of Haematology.